Literature DB >> 2266137

Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein.

K H Weisgraber1, R W Mahley, R C Kowal, J Herz, J L Goldstein, M S Brown.   

Abstract

The binding of native rabbit beta-very low density lipoproteins (beta-VLDL) to the low density lipoprotein receptor-related protein (LRP) requires incubation with exogenous apolipoprotein (apo) E. Inclusion of a mixture of the C apolipoproteins in the incubation inhibits this binding. In the present study, the ability of the individual C apolipoproteins (C-I, C-II, and C-III) to block binding of beta-VLDL to the LRP was examined by measuring cholesteryl ester formation in mutant fibroblasts that lack low density lipoprotein receptors or by measuring binding to the LRP using ligand blotting. In each assay, both apoC-I and apoC-II inhibited binding; apoC-I was the more effective inhibitor. Apolipoprotein C-III had no effect on binding activity, regardless of its sialylation level. Binding of human apoE to rabbit beta-VLDL in the absence or presence of human apoC-I, apoC-II, and monosialo-apoC-III was also determined, by gel filtration and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The results of these studies are consistent with a mechanism in which exogenous human apoE displaces the endogenous apoE and the beta-VLDL particle becomes enriched with apoE (by 4.2-fold in this study). At this higher apoE content, the beta-VLDL bound to the LRP. Inclusion of apoC-I, apoC-II, or apoC-III in the incubation mixture resulted in a differential displacement of apoE from the beta-VLDL; however, at the concentrations examined, only apoC-I and apoC-II were capable of displacing sufficient apoE to abolish binding to LRP.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2266137

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

1.  Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl.

Authors:  N S Shachter; T Ebara; R Ramakrishnan; G Steiner; J L Breslow; H N Ginsberg; J D Smith
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

2.  Isoforms of apolipoprotein C-I associated with individuals with coronary artery disease.

Authors:  D'Vesharronne Moore; Catherine McNeal; Ronald Macfarlane
Journal:  Biochem Biophys Res Commun       Date:  2010-12-25       Impact factor: 3.575

3.  Apolipoprotein CI enhances the biological response to LPS via the CD14/TLR4 pathway by LPS-binding elements in both its N- and C-terminal helix.

Authors:  Jimmy F P Berbée; Claudia P Coomans; Marit Westerterp; Johannes A Romijn; Louis M Havekes; Patrick C N Rensen
Journal:  J Lipid Res       Date:  2010-03-24       Impact factor: 5.922

Review 4.  Disorder-to-order conformational transitions in protein structure and its relationship to disease.

Authors:  Paola Mendoza-Espinosa; Victor García-González; Abel Moreno; Rolando Castillo; Jaime Mas-Oliva
Journal:  Mol Cell Biochem       Date:  2009-04-09       Impact factor: 3.396

5.  Molecular mechanisms responsible for the differential effects of apoE3 and apoE4 on plasma lipoprotein-cholesterol levels.

Authors:  Hui Li; Padmaja Dhanasekaran; Eric T Alexander; Daniel J Rader; Michael C Phillips; Sissel Lund-Katz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02-14       Impact factor: 8.311

6.  Surface composition regulates clearance from plasma and triolein lipolysis of lipid emulsions.

Authors:  I Arimoto; C Matsumoto; M Tanaka; K Okuhira; H Saito; T Handa
Journal:  Lipids       Date:  1998-08       Impact factor: 1.880

7.  The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins.

Authors:  S Ishibashi; J Herz; N Maeda; J L Goldstein; M S Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

8.  Apolipoprotein CI overexpression is not a relevant strategy to block cholesteryl ester transfer protein (CETP) activity in CETP transgenic mice.

Authors:  Thomas Gautier; David Masson; Miek C Jong; Jean-Paul Pais de Barros; Linda Duverneuil; Naig Le Guern; Valérie Deckert; Laure Dumont; Amandine Bataille; Zoulika Zak; Xian-Cheng Jiang; Louis M Havekes; Laurent Lagrost
Journal:  Biochem J       Date:  2005-01-01       Impact factor: 3.857

9.  Aromatic residues in the C-terminal helix of human apoC-I mediate phospholipid interactions and particle morphology.

Authors:  Patrick F James; Con Dogovski; Renwick C J Dobson; Michael F Bailey; Kenneth N Goldie; John A Karas; Denis B Scanlon; Richard A J O'Hair; Matthew A Perugini
Journal:  J Lipid Res       Date:  2008-11-04       Impact factor: 5.922

10.  Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice.

Authors:  N S Shachter; T Hayek; T Leff; J D Smith; D W Rosenberg; A Walsh; R Ramakrishnan; I J Goldberg; H N Ginsberg; J L Breslow
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.